for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ikena Oncology Inc

IKNA.OQ

Latest Trade

14.05USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.07

 - 

37.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.05
Open
--
Volume
--
3M AVG Volume
4.63
Today's High
--
Today's Low
--
52 Week High
37.61
52 Week Low
13.07
Shares Out (MIL)
35.85
Market Cap (MIL)
503.71
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Ikena Oncology Reports Q1 Loss Per Share Of $2.52

Ikena Oncology Inc Shares Open 40% Above IPO Price In Nasdaq Debut

Ikena Oncology Announces Pricing Of IPO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ikena Oncology Inc

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.

Industry

Business Services

Contact Info

50 Northern Ave.

BOSTON, MA

02210

United States

+1.857.3438292

https://www.ikenaoncology.com

Executive Leadership

Ronald C. Renaud

Chairman of the Board

Mark Manfredi

President, Chief Executive Officer, Director, Founding Member

Douglas R. Carlson

Chief Financial Officer

Alfredo Castro

Senior Vice President - Small Molecule Drug Discovery

Michelle Zhang

Senior Vice President - Translational Research and Early Development

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-2.880
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up